Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Angiogenesis in diabetic mouse model with critical limb ischemia; cell and gene therapy.

Asadi-Yousefabad SL., Nammian P., Tabei SMB., Daneshi S., Fallahi J., Razban V.

Animal Study on Peripheral Artery Disease, published in Microvasc Res (2022) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Microvasc Res (2022)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
35151721
DOI
10.1016/j.mvr.2022.104339

Abstract (original English)

Critical limb ischemia (CLI) is the most severe manifestation of peripheral artery disease that diabetes mellitus is one of its major risk factors. MiR-126 as an endothelial cells specific miRNA plays a main role in angiogenesis. The objective of this study was to find a promising treatment by increasing therapeutic potential of adipose tissue mesenchymal stem cells (AT-MSCs) with microRNA-126 in diabetic mouse model with critical limb ischemia. AT-MSCs were isolated from male C57BL/6 mouse and characterized. The cells were infected with miR-126 recombinant lentiviral vectors. Diabetes mellitus type 1 was induced and CLI was created in the animals. Animals were divided in different groups to receive PBS, MSCs, miR-126, and MSC miR-126 and after the experiment, behavioural tests, cell survival, real-time PCR, and histopathological analysis were assessed. The results of function scores, VEGF-A level, and histopathology data demonstrated that the miR-126 treated group was better than PBS and MSCs groups. The expression of PIK3R2 and SPRED1 were decreased in miR-126 group compared to the control group. Our results showed that MSCs miR-126 can live longer than MSCs in the gastrocnemius muscle. We conclude that mice treated with MSCs miR-126 in functional tests showed better results and also the expression of VEGF-A and Microvessel density in them were higher than other groups. This

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsChronic Limb-Threatening IschemiaDiabetes MellitusDisease Models, AnimalEndothelial CellsGenetic TherapyIschemiaMaleMesenchymal Stem Cell TransplantationMice

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research